Amogen Pharma
Hyderabad, India · amogenpharma.com
GLP · GMP
On your own
Free. Their own form.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
Amogen Pharma develops and manufactures recombinant peptide and protein biosimilars for pharmaceutical partners. It operates from Hyderabad, India, with an office in Basel, Switzerland, and serves programs from early development through commercial supply.
Their website has a general contact form; we send your quote request through it.
What they offer
Microbial development services
Genetic engineering, strain development, and microbial development in E. coli and yeast.
Process development
Upstream and downstream process development from bench to commercial scale.
Non-GMP/CGMP manufacturing
Flexible manufacturing from non-GMP toxicology through cGMP clinical and commercial supply.
Microbial manufacturing services
Production of recombinant proteins and peptides with clinical and commercial supply capabilities.
Analytical development
Comprehensive analytical method development, qualification, and transfer.
Microbial analytical services
Bioassays, ELISA, microbiology, molecular biology, and related testing support.
Strain development
Development of high-expressing, stable cell lines and strains.
Cell line development
Proprietary platform processes for generating high-expressing, stable cell lines.
Quality services
GMP batch release testing and supporting quality services across the manufacturing lifecycle.
API supply
Supply of recombinant peptide APIs for long-term partnerships.
FDF licensing
Licensing of finished dosage forms for partner markets.
Co-development
Joint development programs for API and finished dosage form supply.
What they work on
- Modalities
- Small molecule, Peptide, Recombinant protein, Biosimilar
- Species and models
- S. cerevisiae, Saccharomyces cerevisiae, E. coli
- Assays and studies
- UHPLC, HPLC-UV/PDA, LC-MS, HRMS, SEC-HPLC, qPCR, bioassays, ELISA, microbiology, electrophoresis, chromatography, virology, and 2 more
- Instruments and platforms
- UHPLC, HPLC-UV/PDA, LC-MS, HRMS, SEC-HPLC, qPCR, Preparative Chromatography
- Scale and capacity
- 75,000 L total fermentation capacity, 100L pre-seed bioreactor x2, 1000L seed bioreactor x4, 10,000L production bioreactor x5, 4 x 10,000L trains, 15,000L production scale, 980 kg semaglutide API capacity annually, 980 kg GLP-1 fermentation output plant, 5 x 15KL production fermenters
- Therapeutic areas
- GLP-1, insulin, immunology
- Turnaround
- NDA signed within 48 hours
- What to send
- Molecule information · Target markets · Development stage · Volume requirements · Analytical package review under NDA
- Minimums and prices
- Volume-linked pricing
- Type
- CRDMO
- Sites
- Hyderabad, India · Basel, Switzerland
- Team
- 75+ Scientific & Manufacturing Experts
- Quality
- cGMP (microbial production facility) · ICH-compliant (pre-clinical report) · GMP (batch release testing and manufacturing lifecycle)
- Serves
- global, India, UAE, Saudi Arabia, Qatar, Kuwait, Bahrain, Oman, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Canada
- Founded
- 2020
Public records
- Ownership
- AMOGEN PHARMA PRIVATE LIMITED · IN GLEIF
Similar labs. GlycoNex, Inc., Alcami, Alphalyse, Bioneeds
Found in a contract services directory. Listing built from amogenpharma.com. Work here? Claim this listing.